rs746362966

Variant summary

Our verdict is Likely benign. The variant received -5 ACMG points: 0P and 5B. BP4BS2

The NM_001145661.2(GATA2):​c.413T>C​(p.Leu138Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000716 in 1,563,818 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. L138L) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000076 ( 0 hom. )

Consequence

GATA2
NM_001145661.2 missense

Scores

3
7
9

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:5B:1

Conservation

PhyloP100: 1.99

Publications

1 publications found
Variant links:
Genes affected
GATA2 (HGNC:4171): (GATA binding protein 2) This gene encodes a member of the GATA family of zinc-finger transcription factors that are named for the consensus nucleotide sequence they bind in the promoter regions of target genes. The encoded protein plays an essential role in regulating transcription of genes involved in the development and proliferation of hematopoietic and endocrine cell lineages. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Mar 2009]
GATA2 Gene-Disease associations (from GenCC):
  • deafness-lymphedema-leukemia syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp
  • GATA2 deficiency with susceptibility to MDS/AML
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • monocytopenia with susceptibility to infections
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
  • acute myeloid leukemia
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • myelodysplastic syndrome
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -5 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.41186664).
BS2
High AC in GnomAd4 at 5 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GATA2NM_001145661.2 linkc.413T>C p.Leu138Pro missense_variant Exon 4 of 7 ENST00000487848.6 NP_001139133.1
GATA2NM_032638.5 linkc.413T>C p.Leu138Pro missense_variant Exon 3 of 6 ENST00000341105.7 NP_116027.2
GATA2NM_001145662.1 linkc.413T>C p.Leu138Pro missense_variant Exon 3 of 6 NP_001139134.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GATA2ENST00000341105.7 linkc.413T>C p.Leu138Pro missense_variant Exon 3 of 6 1 NM_032638.5 ENSP00000345681.2
GATA2ENST00000487848.6 linkc.413T>C p.Leu138Pro missense_variant Exon 4 of 7 1 NM_001145661.2 ENSP00000417074.1

Frequencies

GnomAD3 genomes
AF:
0.0000329
AC:
5
AN:
152010
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000422
AC:
7
AN:
165748
AF XY:
0.0000450
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000107
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000758
AC:
107
AN:
1411808
Hom.:
0
Cov.:
36
AF XY:
0.0000660
AC XY:
46
AN XY:
697498
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
32730
American (AMR)
AF:
0.00
AC:
0
AN:
36542
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25270
East Asian (EAS)
AF:
0.00
AC:
0
AN:
37506
South Asian (SAS)
AF:
0.0000124
AC:
1
AN:
80590
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
48870
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5308
European-Non Finnish (NFE)
AF:
0.0000930
AC:
101
AN:
1086506
Other (OTH)
AF:
0.0000855
AC:
5
AN:
58486
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.491
Heterozygous variant carriers
0
8
15
23
30
38
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000329
AC:
5
AN:
152010
Hom.:
0
Cov.:
32
AF XY:
0.0000269
AC XY:
2
AN XY:
74228
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41400
American (AMR)
AF:
0.00
AC:
0
AN:
15280
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5138
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4814
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10602
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000735
AC:
5
AN:
67988
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.535
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000777
Hom.:
0
Bravo
AF:
0.0000416
ExAC
AF:
0.0000260
AC:
3

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

GATA2-related disorder Uncertain:1
Mar 27, 2024
PreventionGenetics, part of Exact Sciences
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

The GATA2 c.413T>C variant is predicted to result in the amino acid substitution p.Leu138Pro. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0099% of alleles in individuals of European (Non-Finnish) descent in gnomAD. In ClinVar this variant has been listed as uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/404085/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Deafness-lymphedema-leukemia syndrome;C3280030:Monocytopenia with susceptibility to infections Uncertain:1
Jan 12, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 138 of the GATA2 protein (p.Leu138Pro). This variant is present in population databases (rs746362966, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with GATA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 404085). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GATA2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Predisposition to myelodysplastic syndrome Uncertain:1
Sep 08, 2023
St. Jude Molecular Pathology, St. Jude Children's Research Hospital
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The GATA2 c.413T>C (p.Leu138Pro) missense change has a maximum subpopulation frequency of 0.009% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL is inconclusive about a pathogenic or benign effect of this variant on protein function, and to our knowledge functional studies have not been performed. To our knowledge, this variant has not been reported in individuals presenting with GATA2-associated clinical phenotypes. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -

Deafness-lymphedema-leukemia syndrome Uncertain:1
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. -

Acute myeloid leukemia Uncertain:1
Oct 22, 2023
Baylor Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Oct 28, 2024
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Uncertain
0.029
T
BayesDel_noAF
Uncertain
0.020
CADD
Uncertain
24
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.58
D;.;D;T
Eigen
Benign
0.16
Eigen_PC
Benign
0.22
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Benign
0.79
.;T;T;T
M_CAP
Pathogenic
0.70
D
MetaRNN
Benign
0.41
T;T;T;T
MetaSVM
Uncertain
0.64
D
MutationAssessor
Benign
1.8
L;L;L;.
PhyloP100
2.0
PrimateAI
Pathogenic
0.89
D
PROVEAN
Benign
-1.5
N;N;N;D
REVEL
Uncertain
0.51
Sift
Uncertain
0.0080
D;D;D;D
Sift4G
Benign
0.37
T;T;T;D
Polyphen
0.86
P;P;P;.
Vest4
0.40
MVP
0.83
MPC
1.4
ClinPred
0.20
T
GERP RS
4.5
Varity_R
0.34
gMVP
0.57
Mutation Taster
=69/31
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs746362966; hg19: chr3-128205028; API